Uric Acid to Albumin Ratio for Predicting Contrast Associated Acute Kidney Injury After Cardiac and Non Cardiac Procedures
Predictive Value of the Uric Acid to Albumin Ratio for Contrast Associated Acute Kidney Injury After Cardiac and Non Cardiac Procedures
Contrast-associated acute kidney injury (CA-AKI) is a potential complication that can occur following exposure to iodinated contrast media during diagnostic and interventional procedures, contributing to prolonged hospital stays, increased morbidity, and higher mortality. Although several clinical risk factors are well-recognized, pre-procedural risk stratification remains challenging. The serum uric acid-to-albumin ratio (UAR) has emerged as a composite biomarker reflecting oxidative stress and inflammation that may help identify vulnerable patients prior to contrast exposure.
The primary purpose of this prospective observational cohort study is to evaluate the predictive performance of the pre-procedural uric acid-to-albumin ratio for the development of contrast-associated acute kidney injury. The study will also compare the predictive value of UAR between patients undergoing cardiac procedures, specifically percutaneous coronary intervention (PCI), and those undergoing non-cardiac contrast procedures.
A total of 100 adult participants will be enrolled across two groups: 50 patients undergoing PCI and 50 patients undergoing non-cardiac contrast procedures. Baseline venous blood samples will be obtained prior to the procedure to measure serum creatinine, uric acid, and albumin levels. Follow-up kidney function tests will be evaluated at 48 and 72 hours post-procedure to detect the development of CA-AKI and assess the diagnostic accuracy of pre-procedural UAR.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adult patients admitted to or evaluated at the Internal Medicine Department and related catheterization and interventional units at Assiut University Hospital who are scheduled to undergo cardiac (percutaneous coronary intervention) or non-cardiac diagnostic and interventional procedures requiring exposure to iodinated contrast media.
Descripción
Inclusion Criteria:
- Adult patients aged 18 years or older undergoing a cardiac or non-cardiac procedure requiring iodinated contrast media.
- Cardiac group: patients undergoing percutaneous coronary intervention (PCI).
- Non-cardiac group: patients undergoing other diagnostic or interventional contrast procedures.
- Provision of written informed consent prior to enrollment.
- Available baseline (pre-procedural) serum creatinine, uric acid, and albumin measurements.
Exclusion Criteria:
- Severe chronic kidney disease or end-stage renal disease on regular maintenance hemodialysis (baseline eGFR < 15 mL/min/1.73 m^2).
- Exposure to iodinated contrast media within the preceding 7 to 10 days.
- Acute kidney injury from any cause present at admission or prior to contrast exposure.
- Active infection, sepsis, or systemic inflammatory response syndrome at the time of enrollment.
- Known history of gout, current use of urate-lowering therapy, or hematologic malignancy affecting uric acid metabolism.
- Severe hepatic disease or marked proteinuria affecting serum albumin independently of the study condition.
- Emergent PCI where baseline laboratory samples could not be obtained prior to contrast exposure.
- Patient death occurring before the 48 to 72 hour post-procedural serum creatinine evaluation could be performed.
- Pregnancy.
- Refusal of informed consent or loss to follow-up prior to outcome assessment.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Cardiac Group (PCI)
Adult patients undergoing percutaneous coronary intervention (PCI) requiring exposure to iodinated contrast media. Baseline serum creatinine, uric acid, and albumin are measured pre-procedure, and renal function is monitored at 48 and 72 hours post-procedure to assess the development of contrast-associated acute kidney injury (CA-AKI). |
|
Non-Cardiac Group
Adult patients undergoing non-cardiac diagnostic or interventional procedures requiring exposure to iodinated contrast media. Baseline serum creatinine, uric acid, and albumin are measured pre-procedure, and renal function is monitored at 48 and 72 hours post-procedure to assess the development of contrast-associated acute kidney injury (CA-AKI). |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Contrast-Associated Acute Kidney Injury (CA-AKI)
Periodo de tiempo: 72 hours post-procedure
|
Defined as an absolute increase in serum creatinine of at least 0.5 mg/dL (44.2 micromol/L) or a relative increase of at least 25% from baseline, evaluated within 72 hours following iodinated contrast media exposure. |
72 hours post-procedure
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- UAR in Contrast-Associated AKI
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .